Literature DB >> 18949678

[Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis].

N Guellac1, T Niehues.   

Abstract

UNLABELLED: Treatment of Juvenile Idiopathic Arthritis (JIA) has improved quality of life in children and adolescents suffering from JIA. However, it varies considerably from caregiver to caregiver. Therefore a standardisation of care on the basis of consensus treatment recommendations offers the chance to further improve the quality of care for children and adolescents with JIA. We aimed to establish an interdisciplinary, evidence-based treatment guideline for JIA based on the existing guideline from 2005.
METHODS: We did a systematic literature analysis in PUBMED with the key words "juvenile idiopathic (rheumatoid) arthritis" and "therapy". As limits in PUBMED we used: humans, published in the last 3 years, all child 0-18 years, clinical trial. Studies relating to diagnosis of JIA, Uveitis, vaccination, transition and rofexocibe were excluded. Authors of the 2005 guideline and representatives nominated by different societies were invited to attend the consensus conferences which were hosted by a professional moderator. Following societies were invited: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Consensus conferences took place in Düsseldorf on May 9th and August 1st 2007 and were each attended by more than 95% of the nominated representatives Finally, statements were confirmed in a Delphi method. RESULTS AND
CONCLUSION: Consensus statements regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (EBM).

Entities:  

Mesh:

Year:  2008        PMID: 18949678     DOI: 10.1055/s-0028-1086037

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  7 in total

1.  [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009].

Authors:  G Horneff; T Hospach; G Dannecker; D Föll; J P Haas; H J Girschick; H I Huppertz; R Keitzer; H J Laws; H Michels; K Minden; R Trauzeddel
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

2.  [Recommendations on therapy using interleukin-1beta-blocking agents].

Authors:  B Manger; M Gaubitz; H Michels
Journal:  Z Rheumatol       Date:  2009-11       Impact factor: 1.372

Review 3.  Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Authors:  A Heiligenhaus; H Michels; C Schumacher; I Kopp; U Neudorf; T Niehues; H Baus; M Becker; B Bertram; G Dannecker; C Deuter; I Foeldvari; M Frosch; G Ganser; M Gaubitz; G Gerdes; G Horneff; A Illhardt; F Mackensen; K Minden; U Pleyer; M Schneider; N Wagner; M Zierhut
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

Review 4.  [The importance of biologicals in the treatment of SoJIA].

Authors:  G Dückers; T Niehues
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 5.  [Methotrexate in the therapy of juvenile idiopathic arthritis].

Authors:  D Holzinger; M Frosch; D Föll
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

6.  SEED: the six excesses (Liu Yin) evaluation and diagnosis scale.

Authors:  Pei-Jung Chiang; Tsai-Chung Li; Chih-Hung Chang; Li-Li Chen; Jun-Dai Lin; Yi-Chang Su
Journal:  Chin Med       Date:  2015-10-27       Impact factor: 5.455

Review 7.  Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.

Authors:  Giovanna Ferrara; Greta Mastrangelo; Patrizia Barone; Francesco La Torre; Silvana Martino; Giovanni Pappagallo; Angelo Ravelli; Andrea Taddio; Francesco Zulian; Rolando Cimaz
Journal:  Pediatr Rheumatol Online J       Date:  2018-07-11       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.